Portfolio company
Aprit
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Aprit Biotech develops targeted alpha-particle radio-immunotherapy drugs for the treatment of ovarian cancer patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Aktis Oncology
This biotechnology company develops alpha-emitting radiopharmaceuticals to treat patients with solid tumor cancers.
Full-Life Technologies
This company develops radiopharmaceuticals and radionuclide drug conjugates to treat cancer patients through targeted alpha therapy.
Alpha-9
Alpha-9 Oncology develops targeted radiopharmaceuticals and imaging compounds for the treatment of patients with various types of cancer.
Alpha-9 Theranostics
This clinical-stage biotechnology company develops targeted radiopharmaceuticals to treat cancer patients by delivering radiation directly to tumours while sparing healthy tissue.
Apim Therapeutics
This clinical-stage biotechnology company develops peptide drugs targeting cellular stress responses for patients with advanced cancers including ovarian cancer and sarcoma.
Akiram Therapeutics
This biotech company develops targeted radiopharmaceuticals and radioimmunotherapies for patients with solid tumours and metastatic cancers.
Aprea Therapeutics
This company develops targeted cancer therapies for patients with biomarker-defined tumours and DNA damage response pathway defects.
Ariceum Therapeutics
This clinical-stage biotechnology company develops targeted radiopharmaceutical therapies for the diagnosis and treatment of aggressive, hard-to-treat cancers.